Fortress Biotech — Q3 2026 Earnings Summary

Fortress Biotech reported third-quarter 2026 net revenue of $19.2 million, representing a 9% increase from the prior year period, driven primarily by $18.9 million in product revenue. The company fully repaid its $15.0 million senior secured credit facility with Oaktree in September 2026, leaving it with no outstanding debt at the parent level. Key corporate developments included the in-licensing of FB-607 for irritable bowel syndrome, the approval of anselamimab in Japan for amyloidosis, and a $130 million Series B financing for partner Crystalys Therapeutics. Financial results for the quarter showed a net loss attributable to common stockholders of $7.9 million, while consolidated cash and cash equivalents rose to $152.2 million.